Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer [Phase 1, Phase 2]
A clinical trial update describes a planned first-line treatment for advanced gastric cancer using Fruquintinib in combination with a PD-1 i…
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: A Multicenter Cancer Biospecimen Collection Study
A multicenter cancer biospecimen collection trial sponsored by Cofactor Genomics is currently recruiting, covering multiple cancer indicatio…
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma. [Phase 1]
A Phase 1 trial testing BC001 with Sintilimab and the XELOX regimen for HER-2 negative advanced/metastatic gastric cancer or gastroesophagea…
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients [Phase 1]
Phase 1 clinical trial evaluating CT041 as postoperative adjuvant therapy for gastric and gastroesophageal junction adenocarcinoma; the stud…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. [Phase 1, Phase 2]
Clinical trial update indicating an early-phase study of XNW27011 for multiple advanced solid tumors is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG [Phase 2]
Phase 2 trial evaluating Fruquintinib plus chemotherapy as postoperative treatment for HER2-negative gastric cancer with poor tumor regressi…
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating tislelizumab plus the SOX regimen (S-1 and oxaliplatin) for locally advanced gastric cancer or gastroesoph…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ [Phase 3]
Phase 3 randomized trial update comparing neoadjuvant treatment strategies for locally advanced, potentially resectable gastroesophageal jun…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy [Phase 2]
A phase 2 clinical trial is evaluating the combination of serplulimab, lenvatinib, and paclitaxel as second-line therapy for advanced gastri…
-
CLINICAL_TRIALS research · 2024-12-18Clinical Trial Update: Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ [Phase 2]
Clinical trial update shows sintilimab in combination with chemotherapy with or without local treatment being studied in a Phase 2 trial for…
-
CLINICAL_TRIALS research · 2024-12-12Clinical Trial Update: SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]
Phase 3 trial SHR-A1904 vs investigator's choice therapy is recruiting for Claudin18.2-positive second-line advanced or metastatic gastric o…
-
CLINICAL_TRIALS research · 2024-11-18Clinical Trial Update: A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma [NA]
This clinical trial studies neoadjuvant chemoradiotherapy with hypofractionated radiotherapy for esophageal and gastroesophageal junction ad…
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) [Phase 3]
This is a Phase 3 trial (MK-3475-975/KEYNOTE-975) evaluating pembrolizumab versus placebo in combination with chemotherapy and radiotherapy …
-
CLINICAL_TRIALS research · 2024-11-14Clinical Trial Update: Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma [NA]
This clinical trial update reports the completion of a study evaluating tumor treating fields in combination with chemotherapy as first-line…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) [Phase 3]
This Phase 3 trial (PREVENT) is comparing HIPEC plus FLOT to FLOT alone in gastric cancer and gastroesophageal junction adenocarcinoma. The …
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) [Phase 2]
Phase II trial evaluating the addition of Avelumab to chemotherapy as perioperative treatment for patients with resectable gastric cancer or…
-
CLINICAL_TRIALS research · 2024-10-30Clinical Trial Update: SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer [Phase 2]
A Phase 2 clinical trial is evaluating SHR-A1811 in combination with Apatinib for advanced gastric cancer, gastroesophageal junction adenoca…
-
CLINICAL_TRIALS research · 2024-10-24Clinical Trial Update: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer [Phase 2]
Phase 2 trial assessing oxaliplatin with or without nivolumab in combination with trifluridine/tipiracil or 5-fluorouracil for frail patient…
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer [Phase 1]
First-in-human Phase 1 trial of TORL-2-307-MAB in participants with advanced cancer, including gastric cancer, pancreatic cancer, and gastro…
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1 [NA]
This clinical trial evaluates whether hepatotoxicity and neurotoxicity from oxaliplatin correlate with blood levels of HMGB1 in patients wit…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
A clinical trial is investigating multi-omics predictors of response to immunotherapy plus chemotherapy in advanced gastric cancer and gastr…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of fruquintinib and sintilimab as second-line therapy for gastric cancer and gastroes…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma [Phase 1, Phase 2]
A clinical trial update describes a Phase 1/2 study of AK129, an anti-PD-1 and LAG-3 bispecific antibody, combined with chemotherapy with or…
-
CLINICAL_TRIALS research · 2024-09-05Clinical Trial Update: A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]
This clinical trial update describes a Phase I/II study evaluating Simmitinib or irinotecan liposomes in combination with DP303c for HER2-ex…
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial evaluating disitamab vedotin in combination with trastuzumab in patients with HER2-positive gastric cancer …